JenaValve has appointed Edward (Ed) Sarnowski as its new Chief Technology Officer. He will lead the R&D organization and drive innovation for the company's transcatheter aortic valve programs.
Company Information
Company
JenaValve
Location
Irvine, California, United States
About
JenaValve is a medical device company developing the first transcatheter heart valve technology that is uniquely designed for the minimally invasive treatment of aortic regurgitation (AR).
The JenaValve Trilogy Heart Valve System is the first and only device currently approved in the EU for the treatment of severe, symptomatic aortic regurgitation in patients that are deemed high-risk for surgical aortic valve replacement. The Trilogy System is also CE-Mark approved for treatment of severe, symptomatic aortic stenosis.
In the US, JenaValve has completed enrollment of the ALIGN-AR IDE Clinical Trial which will support a future PMA submission. If approved, the Trilogy System would become the first and only TAVR system in the US indicated for the treatment of symptomatic, severe AR.
Fundz sees it the moment JenaValve changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
IrvineManufacturingInformation TechnologyBiotechnologyHealthcareHealth CareMedical Device